News and Trends 13 Feb 2018 Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly’s Trulicity over to Europe. Eli Lilly executives have said that they are not worried by Novo’s competition, and keep confident on the performance of Trulicity, which now tops 40% of the market share of diabetes drugs belonging […] February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2018 Erytech’s ‘Armed’ Red Blood Cells Will be Tested Against Triple Negative Breast Cancer Erytech will test its Graspa technology for the treatment of a second solid tumor indication, breast cancer, following its success in pancreatic cancer. French biotech Erytech has developed an exciting platform for the treatment of cancer called Graspa, which encapsulates L-asparaginase in red blood cells. The company is now organizing a Phase II study for its next disease […] February 13, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2018 High-Speed Healing Could Prevent the Infection of Chronic Wounds Swedish scientists have used bacteria to deliver a chemical into wounds that speeds up the healing process. This could help to prevent their infection with dangerous strains of resistant bacteria. Researchers at Uppsala University have identified a technique to accelerate the wound healing process and reduce the chance of infection. The study, published in PNAS, […] February 13, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of Germany’s biggest pharma companies, Boehringer Ingelheim, has given up on the development of its Alzheimer’s drug, BI 409306, which underwent Phase II testing. The […] February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development and commercialization of imeglimin, a new treatment for metabolic disorders like type 2 diabetes. Poxel uses its expertise in metabolism to develop drugs for the treatment of disorders like type 2 diabetes. Its candidate imeglimin has caught the eye of […] February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 First Functioning Kidney Tissue Generated from Embryonic Stem Cells Researchers at the University of Manchester have used embryonic stem cells to produce kidney tissue that can filter the blood to produce urine, which opens the door to personalized kidney transplants. Scientists at the University of Manchester have generated human kidney tissue from embryonic stem cells for the first time. The research, published in the journal Stem […] February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 12 Feb 2018 MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert After 25 years, MorphoSys finally got over the line in 2017 with the FDA approval of its first antibody. CEO Simon Moroney tells us how the company hopes to build on its recent success. It may have started out as a tech provider, but MorphoSys now stands as one of the leading German biotechs, specializing […] February 12, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2018 Superbugs: Fighting Antibiotic Resistance at the Science Museum An exhibition at the Science Museum London features some of the deadliest superbugs on Earth and the stories of the people fighting against the threat of antibiotic resistance. It is estimated that, by 2050, 10 million people will die every year due to infections with antibiotic-resistant bacteria. Meaning that the numbers will be higher than […] February 10, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 9 Feb 2018 This Polish Biotech Uses AI to Help Others Speed Up Precision Medicine Development Following on from BioNext’s software last week, we’re in Kraków to visit Ardigen. This biotech develops technology to help us decipher the huge amount of data generated by research. Mission: Ardigen came to our attention when it finished 2nd place in the prestigious NCI-CPTAC DREAM-Proteogenomics Challenge – a competition with more than 500 competitors. Universities and research institutes […] February 9, 2018 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2018 GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […] February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2018 Janssen Biotech Offers up to $1Bn to Irish Biotech for a Bowel Inflammation Drug Janssen Biotech and Theravance Biopharma will develop together a drug to treat bowel inflammation diseases like ulcerative colitis and Crohn’s disease. Janssen Biotech has set its eyes on a drug candidate being developed by the Irish Theravance Biopharma. Both have entered an agreement to co-develop and commercialize the drug. In exchange, Theravance is getting $100M (€82M) […] February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2018 Scottish CAR-T Biotech Adds Another Stellar Partner to Its Roster TC Biopharm has signed a new pharma partner, the Japan-based NIPRO Corporation, who will give the biotech a leg up in the CAR-T game. Hot on the heels of the two huge CAR-T acquisitions of Juno and Kite, Japanese pharma NIPRO Corporation is planting a foot in the game by partnering with Scotland-based TC Biopharm […] February 7, 2018 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email